Improved conjugate vaccines derived from a bacterial immunomodulatory protein

结核病仍然是一个主要的健康和经济负担。关键发现（巴斯大学）和初步疫苗接种研究（纽卡斯尔大学）已经确定，一种被称为Sbi的细菌蛋白（来自金黄色葡萄球菌）可以提高对结核病片段的免疫反应。使我们的Sbi前疫苗成为一个有吸引力的商业机会的是我们的发现，Sbi可以局部激活迄今为止测试的所有哺乳动物的先天免疫系统。因此，使用Sbi开发的疫苗可以用于多个物种，包括牛和人类。 在此，我们将确定Sbi缀合物/化合物在产生针对TB的适当适应性免疫应答方面的成功程度。这些研究将在未来进行全面的结核病挑战实验，这将使我们能够确认Sbi缀合物是用于动物的高效多功能疫苗;为基于新型Sbi缀合物的疫苗的商业化提供明确的途径，以改善动物健康和世界粮食安全。

TB remains a major health and economic burden. Key discoveries (University of Bath) and initial vaccination studies (Newcastle University) have established that a bacterial protein known as Sbi (from Staphylococcus aureus) can improve immune responses to a TB fragment. What makes our Sbi pro-vaccines an attractive commercial opportunity is our findings that Sbi can locally activate the innate immune system of all mammals tested to date. As such, vaccines developed using Sbi could be used across multiple species, including cattle and humans. Here, we will establish how successful Sbi conjugates/compounds are at generating an appropriate adaptive immune response against TB. These studies will lead to full TB challenge experiments in the future, which will allow us to confirm Sbi conjugates as highly effective multifunctional vaccines for animals; providing a clear pathway to commercialization of novel Sbi conjugate based vaccines to improve animal health and world food security.